Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms

Takayuki Hishiki1, Yuko Shimizu, Reiri Tobita

  • 1Research Institute, Chiba Institute of Technology, Narashino City, Chiba 275-0016, Japan. takayuki.hishiki@it-chiba.ac.jp

Journal of Virology
|September 10, 2010
PubMed

Insights

Apolipoprotein E (ApoE) is crucial for Hepatitis C virus (HCV) production and infectivity. ApoE facilitates infectious HCV release from cells, requiring interaction with LDL receptors and SR-BI for efficient viral spread.

Area of Science:

  • Hepatology
  • Virology
  • Biochemistry

Background:

  • Hepatitis C virus (HCV) causes chronic liver disease, cirrhosis, and cancer.
  • HCV associates with lipoproteins like VLDL and LDL in blood.
  • The precise role of lipoproteins in HCV production and infectivity remains unclear.

Purpose of the Study:

  • To investigate the role of apolipoprotein E (ApoE) in the Hepatitis C virus (HCV) life cycle.
  • To determine how ApoE influences HCV production and infectivity.

Main Methods:

  • Analyzed the effect of ApoE knockdown on HCV production.
  • Utilized an ApoE mutant unable to secrete into culture medium.
  • Performed rescue experiments with ectopic expression of different ApoE isoforms.
  • Assessed HCV infectivity in cells with varying LDLR and SR-BI expression.

Main Results:

  • Knockdown of ApoE significantly reduced infectious HCV production.
  • Cells with non-secretable ApoE accumulated infectious HCV intracellularly, indicating ApoE is needed for release.
  • Ectopic expression of ApoE3 and ApoE4 rescued infectious HCV production, unlike ApoE2.
  • HCV infectivity required both LDLR and SR-BI, which are ApoE ligands.

Conclusions:

  • Apolipoprotein E (ApoE) is essential for the production and release of infectious Hepatitis C virus (HCV).
  • Infectious HCV must associate with ApoE before secretion.
  • HCV infectivity depends on the interaction of ApoE with host cell receptors LDLR and SR-BI.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...